MyFinsight
Home
Blog
About
Proceeds from exercise of
tranche a warrants
$10,500,000
Net cash provided by
financing activities
$10,170,362
Canceled cashflow
$329,638
Net decrease in
cash, cash...
-$8,007,684
(-30.97%↓ Y/Y)
Canceled cashflow
$10,170,362
Net loss
$17,466,285
(349.11%↑ Y/Y)
Stock-based compensation
expense
$2,272,840
(281.70%↑ Y/Y)
Proceeds from the
maturity and redemption...
$5,000,000
Payment of deferred
offering costs
$225,318
Costs paid in
connection with private...
$104,320
Net cash used in
operating activities
-$13,344,821
(-118.26%↓ Y/Y)
Canceled cashflow
$19,739,125
Net cash used in
investing activities
-$4,833,225
Canceled cashflow
$5,000,000
Changes in fair value of
the warrant...
-$27,553,204
Prepaid expenses and
other current assets
$3,402,464
(660.28%↑ Y/Y)
Accrued expenses and
other current...
-$1,036,805
(-357.23%↓ Y/Y)
Accounts payable
-$693,740
(2.43%↑ Y/Y)
Accretion of marketable
securities
$397,733
Purchase of marketable
securities
$9,833,225
Back
Back
Cash Flow
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)
source: myfinsight.com